Journal of Clinical Oncology· 2012Q1
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- 1,179citations
- Q1SCImago
- 2012year
Short summary
Decitabine improved complete remission (CR) plus CR without platelet recovery (CRp) rates by 17.8% versus 7.8% in older AML patients (odds ratio 2.5, P=.001), with similar safety to standard treatment choice (TC).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine